Company: FTII
Filing Date: 2025-04-09
Form Type: 10-K
Source: 0001641172-25-003384
Chunk: 520

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-04-09
Form: 10-K
Item: Item 1
Chunk 520
---
 net of the underwriting commissions, discounts, and offering expenses, was deposited in a trust account established for the benefit
of our public stockholders.

On
October 8, 2021, the Company issued an aggregate of 2,875,000 shares of Class B common stock to the Sponsor for an aggregate purchase
price of $25,000 in cash. Such Class B common stock includes an aggregate of up to 375,000 shares that were subject to forfeiture by
the Sponsor to the extent that the underwriters’ over-allotment was not exercised in full or in part, so that the Sponsor would
collectively own at least 20% of the Company’s issued and outstanding shares after the Offering (assuming the initial stockholders
did not purchase any Public Shares in the Offering and excluding the Placement Units and underlying securities). The underwriters exercised
the over-allotment option in full so those shares are no longer subject to forfeiture. Certain officers and directors of the Company
received from the Sponsor certain numbers of Class B common stock as previously disclosed in the Company’s reports with the SEC.
On November 22, 2024, in connection with the Third Extension Meeting (as defined below), all holders of shares of Class B Common Stock
elected to convert such shares of Class B Common Stock into shares of Class A Common Stock on a one-for-one basis. On February 4, 2025,
FutureTech and these holders effected such conversion by delivering the required instructions to FutureTech’s transfer agent.

3

Deadline
to Complete the Company’s Initial Business Combination

As
approved by its stockholders at the Third Extension Meeting held on November 18, 2024, the deadline by which the Company must consummate
an initial business combination is August 18, 2025. The Company held a Special Meeting of Stockholders and amended its Amended and Restated
Certificate of Incorporation (as amended, the “Charter”) three (3) times and extended the deadline by which the Company must
consummate an initial business combination, as fully described in the section below titled “Extension of Combination Period”
under Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Merger
Agreement with Longevity Biomedical Inc.

On
September 16, 2024, the Company, entered into an Agreement and Plan of Merger (the “Merger Agreement”), with Longevity Biomedical,
Inc., a Delaware corporation (“Longevity”), LBI Mer